1. Home
  2. ENTX vs CODA Comparison

ENTX vs CODA Comparison

Compare ENTX & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • CODA
  • Stock Information
  • Founded
  • ENTX 2010
  • CODA 1994
  • Country
  • ENTX Israel
  • CODA United States
  • Employees
  • ENTX N/A
  • CODA N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • CODA Industrial Machinery/Components
  • Sector
  • ENTX Health Care
  • CODA Industrials
  • Exchange
  • ENTX Nasdaq
  • CODA Nasdaq
  • Market Cap
  • ENTX 90.2M
  • CODA 92.5M
  • IPO Year
  • ENTX 2018
  • CODA N/A
  • Fundamental
  • Price
  • ENTX $2.51
  • CODA $7.85
  • Analyst Decision
  • ENTX Strong Buy
  • CODA Strong Buy
  • Analyst Count
  • ENTX 1
  • CODA 1
  • Target Price
  • ENTX $10.00
  • CODA $11.00
  • AVG Volume (30 Days)
  • ENTX 84.8K
  • CODA 29.4K
  • Earning Date
  • ENTX 03-07-2025
  • CODA 03-17-2025
  • Dividend Yield
  • ENTX N/A
  • CODA N/A
  • EPS Growth
  • ENTX N/A
  • CODA 14.29
  • EPS
  • ENTX N/A
  • CODA 0.32
  • Revenue
  • ENTX $99,000.00
  • CODA $20,316,161.00
  • Revenue This Year
  • ENTX N/A
  • CODA $22.31
  • Revenue Next Year
  • ENTX N/A
  • CODA $12.02
  • P/E Ratio
  • ENTX N/A
  • CODA $24.64
  • Revenue Growth
  • ENTX 607.14
  • CODA 4.98
  • 52 Week Low
  • ENTX $0.82
  • CODA $5.48
  • 52 Week High
  • ENTX $3.35
  • CODA $9.89
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 54.94
  • CODA 42.56
  • Support Level
  • ENTX $2.00
  • CODA $7.75
  • Resistance Level
  • ENTX $2.62
  • CODA $8.13
  • Average True Range (ATR)
  • ENTX 0.19
  • CODA 0.28
  • MACD
  • ENTX -0.00
  • CODA -0.03
  • Stochastic Oscillator
  • ENTX 69.35
  • CODA 10.53

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About CODA Coda Octopus Group Inc. Common stock

Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. It operates in two segments: Marine Technology Business and Marine Engineering Business. The Technology Business develops proprietary solutions for both the commercial and defense subsea market. Its solutions include hardware and software for Geophysical Systems, Motion & Positioning Systems, and Real-Time Volumetric Imaging Sonar. The Engineering Business segment provides engineering services to a range of clients in the defense markets. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Marine Technology Business segment.

Share on Social Networks: